Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1618 3797
This examiner grants 41% of resolved cases
Sean R. Donohue is an examiner in Tech Center 3700 and Art Unit 1618. He has 736 resolved cases. The allowance rate is 41.4%. This 41.4% rate reflects the frequency of grants among the 736 cases. Practitioners can use this 41.4% figure to estimate the probability of a successful outcome for their applications.
The median days to allowance is 1213. This 1213-day period is the time from filing to the issuance of a patent. A median of 1213 days serves as a timeline for applicants to consider when their cases are assigned to this examiner. The 1213-day duration is a key metric for budgeting and project management during the prosecution process in Tech Center 3700.
The interview lift is 21.0%. This 21.0% lift shows an increase in the allowance rate when an interview is conducted. A 21.0% lift suggests that direct communication with the examiner is an effective tactic. Practitioners should use this 21.0% figure to justify scheduling an interview to resolve pending rejections and improve the 41.4% base allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18411055 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | Non-Final OA | FUJIFILM Corporation |
| 18690230 | IODIDE NANOPARTICLES AND COMPOSITIONS OF METHODS OF USE THEREOF | Non-Final OA | The University of North Carolina At Chapel Hill |
| 18578434 | LABELED COMPOUNDS AND CALCIUM SENSING RECEPTOR LIGANDS FOR IMAGING AND USES THEREOF | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17550542 | BIOMIMETIC ANISOTROPIC POLYMERIC PARTICLES WITH NATURALLY DERIVED CELL MEMBRANES FOR ENHANCED DRUG DELIVERY | Non-Final OA | The Johns Hopkins University |
| 17264222 | COMPETITIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) BINDING AGENTS FOR REDUCTION OF NON-TARGET ORGAN UPTAKE OF RADIOLABELED PSMA INHIBITORS FOR PSMA POSITIVE TUMOR IMAGING AND RADIOPHARMACEUTICAL THERAPY | Non-Final OA | The Johns Hopkins University |
| 17919848 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | Non-Final OA | The General Hospital Corporation |
| 18554403 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | Non-Final OA | Novartis AG |
| 17922583 | COPPER-CONTAINING THERAGNOSTIC COMPOSITIONS AND METHODS OF USE | Non-Final OA | The University of Melbourne |
| 18398557 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | Final Rejection | NOVOCURE GMBH |
| 17705781 | Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling | Final Rejection | The Government of the United States of America, as represented by the Secretary of the Navy |
| 18343960 | METHODS AND COMPOUNDS FOR DETECTION AND BINDING OF ALDEHYDES | Final Rejection | UNIVERSITY OF OTTAWA |
| 18566471 | ULTRABRIGHT CHEMILUMINESCENT PROBES FOR DETECTION AND IMAGING | Non-Final OA | Nanyang Technological University |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | Non-Final OA | OREGON HEALTH & SCIENCE UNIVERSITY |
| 18247427 | METHODS AND COMPOSITIONS FOR SYNERGISTIC UPTAKE AND RETENTION OF SMALL MOLECULE LIGANDS | Final Rejection | CORNELL UNIVERSITY |
| 18029596 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | Final Rejection | CORNELL UNIVERSITY |
| 18288667 | CANCER-SPECIFIC POLYPEPTIDE AND USE THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17793083 | REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES | Final Rejection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 17793089 | ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING | Final Rejection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 18603721 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES | Final Rejection | Wake Forest University Health Sciences |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy